Characterization of the interaction between the acidic activation domain of VP16 and the RNA polymerase II initiation factor TFIIB.
AUTOR(ES)
Gupta, R
RESUMO
Contact between a transcriptional activator and one or more components of the RNA polymerase II transcription initiation machinery is generally believed important for activators to function. Several different molecular targets have been suggested for direct contact by herpes simplex virus virion protein VP16, including the general initiation factor TFIIB. In this report we have used several strategies to critically assess this interaction between VP16 and TFIIB. Affinity columns of VP16 bound TFIIB activity from HeLa cell extracts and the binding was reduced by mutations in the activation domain of VP16. In assays of direct binding, VP16 bound recombinant human TFIIB but not Drosophila or yeast TFIIB. Unlike binding from an extract, however, we found that the interaction between VP16 and recombinant human TFIIB was not affected by mutations in VP16 that reduce transactivation. Point mutations within human TFIIB that reduce transactivation by VP16 have been shown to reduce VP16 binding, but we show here that these same mutations critically affect both the important TBP-TFIIB interaction and the ability of TFIIB to support activator-independent basal transcription in vitro. Taken together our results suggest more evidence is needed to support the notion that TFIIB is a functionally important target for the activator VP16.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=145954Documentos Relacionados
- Potential RNA polymerase II-induced interactions of transcription factor TFIIB.
- RNA polymerase II initiation factor alpha from rat liver is almost identical to human TFIIB.
- Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53.
- Concerted activity of host cell factor subregions in promoting stable VP16 complex assembly and preventing interference by the acidic activation domain.
- Activation of yeast polymerase II transcription by herpesvirus VP16 and GAL4 derivatives in vitro.
